Cell2Cure

Executive Summary

Cell2Cure is a clinical-stage Danish biopharmaceutical company pioneering off-the-shelf, allogeneic cell therapies based on adipose-derived mesenchymal stromal/stem cells (MSCs). Its platform targets diseases characterized by inflammation, immune dysregulation, and tissue damage, addressing significant unmet medical needs. The lead product candidate, C2C_ASC, is undergoing multiple Phase I and II trials, with early data suggesting potential in modulating immune responses and promoting tissue repair. The company's focus on scalable, allogeneic manufacturing positions it to overcome key limitations of autologous cell therapies, offering a cost-effective and readily available treatment option. Despite being in early clinical stages, Cell2Cure's innovative approach and diverse pipeline across inflammatory and degenerative indications provide a strong foundation for future growth.

Upcoming Catalysts (preview)

• Q4 2026Phase I/II interim data readout for C2C_ASC in graft-versus-host disease50% success
• Q1 2027Initiation of Phase II trial for C2C_ASC in osteoarthritis70% success
• H2 2027Strategic partnership for manufacturing scale-up or regional commercialization40% success